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Abstract: Protoflavones, a rare group of natural flavonoids with a non-aromatic B-ring, are best
known for their antitumor properties. The protoflavone B-ring is a versatile moiety that might be
explored for various pharmacological purposes, but the common cytotoxicity of these compounds
is a limitation to such efforts. Protoapigenone was previously found to be active against the lytic
cycle of Epstein–Barr virus (EBV). Further, the 5-hydroxyflavone moiety is a known pharmacophore
against HIV-integrase. The aim of this work was to prepare a series of less cytotoxic protoflavone
analogs and study their antiviral activity against HIV and EBV. Twenty-seven compounds, including
18 new derivatives, were prepared from apigenin through oxidative de-aromatization and subsequent
continuous-flow hydrogenation, deuteration, and/or 4′-oxime formation. One compound was active
against HIV at the micromolar range, and three compounds showed significant activity against the
EBV lytic cycle at the medium-low nanomolar range. Among these derivatives, protoapigenone
1′-O-isopropyl ether (6) was identified as a promising lead that had a 73-times selectivity of antiviral
over cytotoxic activity, which exceeds the selectivity of protoapigenone by 2.4-times. Our results open
new opportunities for designing novel potent and safe anti-EBV agents that are based on the natural
protoflavone moiety.
Keywords: natural product; drug discovery; protoflavonoid; continuous-flow chemistry; oxime;
antitumor; antiviral; Epstein–Barr virus; lytic cycle
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1. Introduction
Protoflavonoids represent a relatively rare, naturally occurring group of flavonoids, which possess
a non-aromatic B-ring and a hydroxyl function at C-1′. This unique structural moiety can appear in
various forms, it is most typically a symmetric dienone p-quinol that may be partially or fully saturated,
as shown by the examples of some natural protoflavones illustrated in Figure 1 [1].
Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 2 of 13 
 
appear in various forms, it is most typically a symmetric dienone p-quinol that may be partially or 1 
fully saturated, as shown by the examples of some natural protoflavones illustrated in Figure 1 [1]. 2 
 3 
Figure 1. Examples of natural protoflavones with different moieties in their B-ring. A symmetric 4 
dienone structure, as in protoapigenone, is prerequisite of a strong cytotoxic activity. 5 
Many protoflavones are known for their potent anticancer activity and, until now, this is the 6 
bioactivity that is by far the most deeply investigated for this compound family. Protoflavones are 7 
known to be cytotoxic on a wide range of cancer cell lines in vitro, and some can selectively kill multi-8 
drug resistant cancer cell lines that are adapted to chemotherapeutics [2,3]. Some protoflavones, e.g., 9 
protoapigenone, were also tested in vivo and found active against a variety of tumor xenograft 10 
models [1]. A particularly interesting pharmacodynamic property of protoapigenone is that it is a 11 
potent inhibitor of the ATR-mediated activation of checkpoint kinase 1 (Chk1) [4], a DNA damage 12 
response mechanism that is an emerging antitumor target in the focus of several currently ongoing 13 
clinical trials [5]. 14 
From the available structure-activity relationships that were obtained from synthetic [6] and 15 
semi-synthetic [7] analogs, it is known that a) presence of a symmetric dienone with a non-substituted 16 
p-quinol B-ring is essential for a strong cytotoxic effect [8], b) the presence of a longer non-branching 17 
(e.g., butyl) alkyl substituent at the 1′-OH can further enhance cytotoxicity against some cell lines, 18 
and c) a branching 1′-O-alkyl substituent (e.g., isopropyl) strongly decreases cytotoxicity. It is also 19 
worth noting that a 1′-O-alkyl substitution results in a chemically much more stable B-ring when 20 
compared to the non-substituted p-quinol [7]. 21 
However, the possible use of protoflavonoids might exceed their antitumor potential. The non-22 
aromatic B-ring containing an sp3 carbon at C-1′ makes the three-dimensional (3D) structure of these 23 
compounds very unique among flavonoids. This might lead to a versatile pharmacology that is 24 
hardly explored. Previously, we identified protoapigenone 1′-O-propargyl ether as the first non-25 
planar flavonoid that can exert a potent inhibitory effect on xanthine oxidase, a pro-oxidant enzyme 26 
that is involved in many chronic diseases [9]. In addition to this, we found that protoapigenone exerts 27 
an antiviral effect against the Epstein–Barr Virus (EBV) in vitro through inhibiting the expression of 28 
EBV lytic proteins [10]. These results suggest that the chemical space of protoflavones has still much 29 
to offer in bioactivities other than antitumor effect, while cytotoxicity itself certainly represents a 30 
limitation for exploring these. 31 
We recently reported a method for the highly selective saturation of the protoflavone B-ring by 32 
means of continuous flow hydrogenation under mild reaction conditions to overcome this limitation. 33 
This allowed for us to obtain the rare, naturally occurring tetrahydroprotoflavone moiety, while also 34 
providing an effective tool to eliminate the cytotoxicity of the derivatives [11]. 35 
The aim of our current work was to further explore the antiviral potential of protoflavonoids by 36 
preparing a series of less cytotoxic derivatives, and then test them against EBV and, while considering 37 
the antiretroviral activity of various other types of flavonoids [12–14], also against HIV. 38 
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dienone structure, as in protoapigenone, is prerequisite of a strong cytotoxic activity.
Many protoflavones are known for their potent anticancer activity and, until now, this is the
bioactivit that is by far the most deeply investigated for this compound family. Protoflavone ar
known to be cytotoxic on a wide range of cancer cell lines in vitro, a so e can selectively kill
multi-drug resistant cancer cell lines that are adapted to chemotherapeutics [2,3]. Some protoflavones,
e.g., protoapigenone, were al o tested in vivo and found active against a variety of tumor xenograft
m dels [1]. A particularly inter sti g pharmacody amic property of protoapigenone is that it is a
potent inhibitor of the ATR-mediated activation of checkpoint kinase 1 (Chk1) [4], a DNA damage
response mechanism that is an emerging antitumor target in the focus of several currently ongoing
clinical trials [5].
From the available structure-activity relationships that were obtained from synthetic [6] and
semi-synthetic [7] n logs, it is known that (a) presence of a symmetric die one with a non-substitute
p-quinol B-ring is essential for a strong cytotoxic effe t [8], (b) the presence of a longer non-branching
(e.g., butyl) alkyl substituent at the 1′-OH can further enhance cytotoxicity gainst some cell lines,
and (c) a branching 1′-O-alkyl substituent (e.g., isopropyl) strongly decreases cytotoxicity. It is also
worth noting t at a 1′-O-alkyl substitution results in a chemicall much more stable B-ring when
compared to the non-substituted p-quinol [7].
However, the possible use of protoflavonoids might exceed their antitumor potential.
The non-aromatic B-ring containing an sp3 carbon at C-1
′
makes the three-dimensional (3D) structure
of these compounds very unique among flavonoids. This mig t l a to a versatile pharmacology that is
hardly explored. Previo sly, we identified protoapigenone 1′-O-pr pargyl ether as the first non-pl nar
fl vonoid that can exert a potent inhibitory effect on xanthine oxidase, pro-oxidant enzyme that is
involved in many chronic diseases [9]. I addition to this, we fou d that protoapigenone exerts an
antiviral effect against the Epstein–Barr Virus (EBV) in vitro through inhibiting the ex ressi of EBV
lytic proteins [10]. These results suggest that the chemical space of pr toflavones has still much to offer
in bioactivities other than antitumor effect, while cytotoxicity itself certainly represe ts a limitation for
exploring these.
We recently reported a method for the highly selective saturation of the protoflavone B-ring by
means of continuous flow hydrogenation under mild reaction conditions to overcome this limitation.
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This allowed for us to obtain the rare, naturally occurring tetrahydroprotoflavone moiety, while also
providing an effective tool to eliminate the cytotoxicity of the derivatives [11].
The aim of our current work was to further explore the antiviral potential of protoflavonoids by
preparing a series of less cytotoxic derivatives, and then test them against EBV and, while considering
the antiretroviral activity of various other types of flavonoids [12–14], also against HIV.
2. Results and Discussion
2.1. Synthesis of B-Ring Modified Protoapigenone Analogs
First, we prepared the 1′-O-alkyl substituted protoapigenone derivatives from apigenin (1),
following our previously described procedure [7]. Oxidative dearomatization of the B-ring of apigenin
was achieved by a hypervalent iodine reagent, [bis(trifluoroacetoxy)iodo]benzene, and the solvent
was 10% v/v of water or alcohol in acetonitrile depending on the substituent to be coupled at C-1′.
This allowed for us to obtain compounds 2–8 as potential intermediates for further transformations,
among which 6 was already a compound of interest for this study due to its very weak cytotoxicity
when compared to the others.
As detailed above, the function that is dominantly responsible for the cytotoxicity of protoflavones
is the symmetric dienone moiety on the B-ring, conferring pro-oxidant and Micheal-acceptor properties
to the compound. While considering this, we employed two different targeted synthetic strategies for
eliminating cytotoxicity: (i) Saturation of the double bonds through hydrogenation or deuteration and
(ii) substituting the 4′-oxo group with an oxime function. Scheme 1 shows synthetic routes.
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continuous flow hydrogenation reactor [11]. Employing this device has several advantages when 26 
compared to traditional batch hydrogenation, i.e., the ease of handling of the explosive gas, precise 27 
control over the reaction conditions, instrumentally controlled gas pressure, sustainability, and safe 28 
applicability. During this process, hydrogen gas was in situ generated by an electrolytic cell fueled 29 
with high purity water, and forwarded to interact with the substrate’s solution. The mixture was then 30 
passed through a stainless-steel tube that was filled with the catalyst, where the triphasic reaction 31 
took place. During each transformation, the catalyst bed was placed in a thermostat to assure 32 
Scheme 1. Semi-synthetic routes employed for the preparation of tetrahydro-, tetradeutero- or
4′-oxime analogs of protoapigenone and its 1′-O-alkyl ether derivatives. Oxime derivatives 21–28
were t ined as racemates, how ver, for simplicity only o e enantiomer is shown. Reaction conditions:
(a) CH3CN/RO —9: , ◦ , 1 ; (b) H-Cube®, 9–14: H2, 5% Pd/C or 15−20: D2, 5%
Pd/BaSO4; (c) NH2OH· Cl (3 equiv.), Me , fl , 24 h; and, (d) NH2OH·HCl (4 equiv.), MeOH,
reflux, 3 h.
The hydrogenation of protoflavonoids’ dienone moiety might result various products.
Following our previously published procedure, the saturation of the protoflavone B-ring was achieved
with high selectivity under mild reaction conditions while utilizing a modified H-cube® continuous
flow hydrogenation reactor [11]. Employing this device has several advantages when compared to
traditional batch hydrogenation, i.e., the ease of handling of the explosive gas, precise control over
the reaction conditions, instrumentally controlled gas pressure, sustainability, and safe applicability.
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During this process, hydrogen gas was in situ generated by an electrolytic cell fueled with high
purity water, and forwarded to interact with the substrate’s solution. The mixture was then passed
through a stainless-steel tube that was filled with the catalyst, where the triphasic reaction took place.
During each transformation, the catalyst bed was placed in a thermostat to assure temperature control.
Products of the reactions were collected into glass vials and subsequently purified by RP-HPLC to
obtain tetrahydroprotoapigenone analogs 9–14 in high purity (Scheme 1).
Deuterium is applied in organic chemistry for several purposes. It is employed as a tracer in
studies that aim to follow the reaction routes or as a reference for determining the influence of isotope
effects on the development of a reaction during kinetic studies. Isotope labeling is a versatile technique
that can be used many ways, including e.g., metabolomic studies, and the importance of deuterium in
isotope labeling is increasing as new applications emerge [15,16].
Deuterium can also be of potential interest for discovery, since it can significantly influence
bioactivity of a compound due to the so-called isotope effect [17,18]. Several methods are available for
the synthetic preparation of deuterium containing compounds. The conventional batch synthesis of
deuterated molecules suffers from similar drawbacks as hydrogenation, such as the lack of sustainability
and the low purity and high price of D2 gas. Therefore, we used a previously established continuous-flow
method in this current work [19–21], during which the required deuterium gas was in situ generated
from high-purity D2O with H-Cube®. The reaction was performed in an aprotic solvent, ethyl acetate,
to ensure that no hydrogen-deuterium exchange occurs during the transformation. For the same
reason, we chose barium sulfate as the catalyst carrier, since activated charcoal might contain protic
contaminations on its surface. In all other aspects of the synthesis, we followed the same procedure as
in the case of hydrogenation, to obtain tetradeuteroprotoapigenone derivatives 15–20 (Scheme 1).
Several studies underline that the preparation of flavonoid oxime derivatives can be a simple
yet effective synthetic option for enhancing certain biological effects of the parent compound, e.g.,
antimicrobial [22], antioxidant [23], and antitumor [24] properties. Compounds with different B-ring
saturation and/or 1′-O-substituents (6–9 and 14) were selected for the preparation of 4′-oximes to
further increase chemical and consequential pharmacological diversity (Scheme 1).
Our preliminary small-scale test reactions indicated that oxime formation of protoflavones is
regioselective at the 4′-keto group, and under the synthetic conditions applied, we did not observe
the formation of 4-oxime nor 4,4′-dioxime side products. On the other hand, the solvent appeared to
play a crucial role in the possible outcome of the transformation. Pyridine, ethanol, and acetonitrile
are probably among the most commonly used solvents in oxime synthesis. However, none of these
worked in our case and, finally, we found methanol to be the best solvent for reacting protoflavones
with hydroxylamine. The yields appeared to vary greatly, depending on the substrate’s concentration
in the reaction solution, and we obtained the best yields with ca. 2–2.5 mg/mL concentrations; both
lower and higher concentrations could significantly decrease the efficiency of the transformation.
Regioselective transformation of the tetrahydroprotoflavone analogs 9 and 14 to their
corresponding 4′-oximes 27 and 28 was straightforward. However, in the case of protoflavones 6–8, each
transformation was accompanied by a regioselective Michael addition of methanol at C-2′, forming a
methoxy group and saturating one of the double bonds to yield 2′-methoxy-2′3′-dihydroprotoapigenone
4′-oxime derivatives 21–26. The orientation of the methoxy group was apparently random, since the
1′,2′-cis and trans derivatives were formed in a ca. 1:1 ratio. When assigning the relative configuration
of the 1′,2′-carbon atoms, we could not observe diagnostic NOESY cross-peaks between the 2′-methoxy
and the 1′-O-alkyl substituents for any of these compounds. Therefore, cis-trans isomers were assigned
based on the characteristic coupling constant patterns that were observed between H-2′ and H-3′a
or H-3′b. To achieve this, structures were optimized by the MMFF94x force field in CCG-MOE,
the H2′-C2′-C3′-H3′a, and H2′-C2′-C3′-H3′b dihedral angles were measured, and theoretical 1H-1H 3J
coupling constants were calculated by means of the Bothner-By equation. The experimental coupling
constants showed good agreement with the calculated values, unambiguously assigning compounds
21–23 as the 1′,2′-trans, and 24–26 as the 1′,2′-cis isomers. Nevertheless, while each compound was
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obtained as racemate, the newly formed oxime took a defined orientation in all of them. This suggests
that the solvent addition took place to an intermediate of the reaction in a way that it determined
the final orientation of the oxime. We considered compounds 27 and 28 as internal references, since
the exact data of the ∆δ syn-anti parameters were not available this way, which provided us with the
chemical shifts for both neighbouring methylenes of the oxime. In these compounds, C-3′ (syn) and
C-5′ (anti) gave 13C NMR chemical shifts at ca. 18.8 and 26.2 ppm, respectively. The 13C NMR signals of
the 3′-CH2 moieties of compounds 21–26 appeared within the range of 22.7–23.7 ppm, which strongly
suggests that the oxime is present in E-orientation in each of these compounds while also taking the
effect of the electron-rich neighbouring OCH3 group into account.
2.2. Biological Activities
2.2.1. Antiretroviral Activity
Compounds 2, 6–14, and 21–28 were tested against HIV-1 while using a pseudotype virus assay
allowing only one cycle of viral replication and being more sensitive for compounds targeting the early
steps of HIV replication, such as reverse transcription and integration [25]. Tetrahydroprotoapigenone
(9) was found to inhibit viral infection by ca. 50% at the non-cytotoxic concentration of 100 µM (see
Supplementary Materials, Table S1). While this represents a rather weak activity, it might still be of
interest, since this compound was not cytotoxic on the host cells at as high as 500 µM concentration.
2.2.2. Antiviral Activity against EBV
Compounds 2 and 6–28 were tested for their activity on the EBV lytic cycle. To assess this,
the P3HR1 cells were treated with sodium butyrate and TPA for 24 h. As expected, lytic protein Rta
was expressed after lytic induction. As a first screening, the cells were treated with protoapigenone (2),
used as a positive control, or compounds 6–28 at the induction of lytic cycle for 24 h. The concentration
selected for screening was 0.25 µM, where protoapigenone (2) was previously found to exert a strong
activity [10]. The results indicated that three of the analogs, 6, 7, and 8 can inhibit EBV lytic cycle at
this concentration. These compounds were then tested for the dose dependency of their effect on the
expression of Rta; Figure 2 shows the results.
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Figure 2. Inhibition of the expression of Epstein–Barr Virus (EBV) Rta by protoapigenone (2) and its
analogs 6–8. The cells were treated with the compounds at the time of lytic induction with SB and
TPA. Cell lysates were harvested at 24 h after lytic induction. Proteins in the lysate were detected by
immunoblotting using anti-Rta and anti-α-tubulin antibodies. Calculated IC50 values for 2, 6, 7, and 8
were 0.127, 0.467, 0.208, and 0.285 µM, respectively.
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We found that, similarly to protoapigenone (2), compounds 6, 7, and 8 also caused a marked
reduction in the Rta levels at 0.50, 0.25, and 0.50 µM, respectively, and the IC50 values were calculated
as 0.467, 0.208, and 0.285 µM, respectively. The positive control protoapigenone (2) acted with an IC50
value of 0.127 µM, which was in good agreement with our previous findings [10]. Subsequently, we
conducted MTT assay to evaluate the cytotoxicity of these compounds to P3HR1 cells; Figure 3 shows
the results.
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Compounds 7 and 8 were similarly active as protoapigenone, as expected from our previously
published structure-activity relationship (SAR) study on the effect of 1′-O-alkyl substituents on the
cytotoxic activity of protoflavones [7] (2), and the isopropyl-ether derivative 6 was much weaker in
this regard. Selectivity of the anti-EBV vs. cytotoxic effect of these compounds, expressed as a ratio
of the corresponding IC50 values, could therefore be calculated, as follows: 2 (30.1), 6 (73.0), 7 (9.80),
and 8 (17.3). This means that compound 6 demonstrated a relevant, ca. 2.6-times increase in selectivity
when compared to protoapigenone. It needs to be stressed that this selectivity increase is due to the
much weaker cytotoxic activity of compound 6 as compared to protoapigenone, and it does not refer
to a stronger anti-EBV activity. While this successfully fulfills our objectives that were set for this
study, it might be worthy to further explore SAR regarding the role of the 1′-O-alkyl chain in the future.
For example, when considering that the 1′-O-butyl derivative compound 7 exerted an over two-fold
stronger anti-EBV activity than the 1′-O-isopropyl compound 6, it might be a relevant strategy to study
further analogs with a longer branching side-chain coupled at C-1′, such as i-butyl, i-pentyl, etc.
It is also worth noting that it was also found to be possible to shift the bioactivity profile of
protoflavones to the other direction, i.e., increasing cytotoxicity and decreasing anti-EBV activity, by
appropriate modifications of the B-ring. As compared with protoapigenone (2), compound 7 was less
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effective against EBV and more cytotoxic, i.e., ca. three-times less selective in this regard. Therefore,
the SAR of protoflavonoids might be explored towards various therapeutic targets, and this is certainly
a need to evaluate their real value concerning drug discovery.
3. Materials and Methods
3.1. Synthesis and Chromatographic Purification
Reagents were purchased from Sigma (Merck KGaA, Darmstadt, Germany) and the solvents were
obtained from Macron Fine Chemicals (Avantor Performance Materials, Center Valley, Pennsylvania,
USA). The reactions were monitored by TLC on Kieselgel 60F254 silica plates purchased from Merck
(Merck KGaA, Darmstadt, Germany), and characteristic spots of compounds were examined under
UV illumination at 254 and 366 nm. Chromatographic purification of components was carried out
in one or two steps, depending on the complexity of protoflavone product mixtures. For flash
chromatography, a CombiFlash® Rf+ Lumen apparatus (TELEDYNE Isco, Lincoln, NE, USA) was
utilized that was equipped with ELS and diode array detectors. Components were separated on
commercially available RediSep NP-silica flash columns (TELEDYNE Isco, Lincoln, NE, USA) or
manually filled polyamide columns. The mobile phase eluents consisted of mixtures of n-hexane—ethyl
acetate or dichloromethane—methanol, modified according to the polarity of the analytes. To determine
the composition of sample mixtures or to evaluate the purity of compounds, RP-HPLC analysis was
performed on a Kinetex XB-C18 250 × 4.6 mm, 5 µm or a Kinetex Biphenyl 250 × 4.6 mm, 5 µm column
(Phenomenex Inc., Torrance, CA, USA) at 1 mL/min. flow rate, while using a dual pump (PU-2080)
Jasco HPLC instrument (Jasco International Co. Ltd., Hachioji, Tokyo, Japan) that was equipped with
an MD-2010 Plus PDA detector to collect data in a detection range of 210–400 nm. For preparative
purposes, an Armen Spot Prep II integrated HPLC purification system (Gilson, Middleton, WI, USA)
with dual-wavelength detection was applied, operating at 230 and 300 nm. Preparative separations
were performed on the corresponding Kinetex XB-C18 or Biphenyl 250 × 21.2 mm, 5 µm columns with
adequately chosen eluents of acetonitrile–water, and the flow rates were 15 mL/min.
3.1.1. Preparation of Protoapigenone Derivatives 2–8
Protoapigenone and its 1′-O-alkyl ether analogs were synthesized while following our previously
described procedures [7]. Briefly, apigenin (1 mg/mL) was dissolved in a 9:1 v/v ratio mixture
of acetonitrile and H2O or the alcohol to be coupled at C-1′. Under stirring, two equivalents of
[bis(trifluoroacetoxy)iodo]benzene was added slowly to the solution and the reaction was left to
develop for 1 h at 80 ◦C. After completion, the solvent was evaporated on a rotary evaporator and the
residue was purified by flash chromatography, allowing for obtaining the corresponding protoflavones
in pure form.
3.1.2. Preparation of Tetrahydroprotoapigenone Derivatives 9–14
Selective hydrogenation of protoflavones was carried out based on our previous strategy [11] that
relied on the application of an H-Cube® continuous flow hydrogenation system (ThalesNano Inc.,
Budapest, Hungary). The applied catalyst cartridge was a stainless-steel column (internal dimensions:
50 mm × 4.6 mm) containing approximately 200 mg of 5% Pd/C catalyst. The cartridge was inserted
into an external thermostat (Jetstream 2 plus, Jasco International Co. Ltd., Hachioji, Tokyo, Japan) set
to 25 ◦C. A standard HPLC pump (Well-Chrom K-120, Knauer GmbH, Berlin, Germany) was used to
provide continuous stream. In each case, the flow rate was set to 1 mL/min., and 40 bar pressure was
applied in the system.
For each reaction, 20 mg of the corresponding protoflavone was dissolved/suspended in 20 mL
of HPLC grade ethyl acetate and homogenized by sonication. The catalyst bed was washed with
the solvent for 15 min. to ensure reproducibility between each reaction. Following transformations,
preparative RP-HPLC was utilized for chromatographic purification.
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3.1.3. Preparation of Tetradeuteroprotoapigenone Derivatives 15–20
The selective deuteration of the protoflavone B ring was performed similarly to that described for
hydrogenation with only slight modifications. In this case, approximately 400 mg of 5% Pd/BaSO4
was used as a catalyst, and the reservoir of the instrument was filled up with high purity heavy water
(D2O). The obtained compounds 15–20 were purified by preparative RP-HPLC.
3.1.4. Preparation of Protoflavone 4′-oxime Derivatives 21–26
An aliquot of 150 mg of compound 6, 7, or 8 was dissolved in methanol in a concentration of
2.5 mg/mL (50 mL). Following this, three equivalents of hydroxylamine hydrochloride were added
to the solution, and the mixture was refluxed for 24 h at 70 ◦C. Silica gel (3–5 g) was added to the
solution and the solvent was evaporated to prepare for dry loading separation. The dried residue was
applied to flash chromatography, and products were pre-purified by a gradient separation program
starting with n-hexane, and the ratio of ethyl acetate was gradually increasing 90%, v/v, in 15 min.
Following this, cis- and trans-isomeric racemate pairs (21 and 24, 22 and 25, 23, and 26, respectively)
were separated by means of preparative RP-HPLC to obtain racemates 21–26.
3.1.5. Preparation of Tetrahydroprotoflavone 4′-oxime Derivatives 27–28
An aliquot of 60 mg of tetrahydroprotoflavone 9 or 14 was dissolved in methanol in a concentration
of 2.5 mg/mL (25 mL). Four equivalents of hydroxylamine hydrochloride were added to the mixture
and the solution was stirred at 70 ◦C for 3 h. Following this, solvent was evaporated on a rotary
evaporator and brine (40 mL) was added to the residue. Extraction was performed with EtOAc
(3 × 40 mL), and the organic fractions were then combined and dried over Na2SO4. The drying agent
was removed through filtration, and the solution was evaporated under reduced pressure. Eventually,
preparative RP-HPLC was applied to obtain oxime derivatives 27 and 28.
3.2. Structure Elucidation
NMR and MS techniques characterized the compounds. NMR spectra were recorded at 25 ◦C on
a Bruker Avance DRX 400 MHz (Bruker Co., Billerica, MA, USA) or on a Bruker Avance NEO 500 MHz
spectrometer that was equipped with a Prodigy BBO 5 mm CryoProbe with the use of TMS as an
internal standard. Typically, 5–10 mg of the corresponding protoflavone was dissolved in DMSO-d6
and transferred to NMR tubes for recording spectra. The data report and spectra analysis were carried
out with MestReNova v6.0.2-5475 software (Mestrelab Research S.L., Santiago de Compostela, Spain).
1H and 13C NMR chemical shifts are listed below; residual hydrogen signals of the B-rings of deuterated
compounds 15–20 are marked with an asterisk. Mass spectra were recorded on an API 2000 triple
quadrupole tandem mass spectrometer (AB SCIEX, Foster City, CA, USA) that was equipped with
ESI ion source that was used in the negative ionization mode. 1H and 13C (JMOD) spectra of the
new compounds are provided as Supplementary Materials, Figures S1–S36, and their mass spectra as
Figures S37–S54.
Compound 10: Pale yellow solid, Isolated yield: 25.2% (5.1 mg); RP-HPLC purity: 97%. 1H NMR
(500 MHz, DMSO-d6): 12.65 (1H, s), 10.93 (1H, br s), 6.39 (1H, d, J = 1.9 Hz), 6.34 (1H, s), 6.20 (1H, d,
J = 1.9 Hz), 3.22 (3H, s), 2.56 (2H, m), 2.35 (2H, m), 2.18–2.22 (4H, m). 13C NMR (125 MHz, DMSO-d6):
208.9, 181.7, 168.9, 164.5, 161.4, 157.8, 107.5, 103.9, 99.0, 94.1, 75.7, 51.0, 2 × 35.8, 2 × 30.8. ESI-MS (m/z):
303.4 [M-H]−.
Compound 11: Pale yellow solid, Isolated yield: 70.5% (15.5 mg); RP-HPLC purity: 98%. 1H NMR
(500 MHz, DMSO-d6): 12.66 (1H, s), 10.94 (1H, br s), 6.39 (1H, d, J = 1.9 Hz), 6.32 (1H, s), 6.20 (1H, d,
J = 1.9 Hz), 3.40 (2H, q, J = 6.9 Hz), 2.55 (2H, m), 2.34 (2H, m), 2.16–2.22 (4H, m), 1.16 (3H, t, J = 6.9 Hz).
13C NMR (125 MHz, DMSO-d6): 209.0, 181.7, 169.6, 164.5, 161.4, 157.7, 107.1, 103.8, 99.0, 94.0, 75.5, 58.6,
2 × 35.9, 2 × 31.3, 15.5. ESI-MS (m/z): 317.7 [M-H]−.
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Compound 12: Pale brown solid, Isolated yield: 30.1% (6.1 mg); RP-HPLC purity: 99%. 1H NMR
(500 MHz, DMSO-d6): 12.65 (1H, s), 10.97 (1H, br s), 6.38 (1H, d, J = 1.9 Hz), 6.32 (1H, s), 6.20 (1H, d,
J = 1.9 Hz), 3.30 (2H, t, J = 6.4 Hz), 2.56 (2H, m), 2.36 (2H, m), 2.16–2.22 (4H, m), 1.55 (2H, m), 0.89 (3H,
t, J = 7.4 Hz). 13C NMR (125 MHz, DMSO-d6): 209.0, 181.7, 169.3, 164.6, 161.4, 157.7, 107.3, 103.8, 99.0,
94.0, 75.2, 64.5, 2 × 35.9, 2 × 31.2, 22.8, 10.7. ESI-MS (m/z): 331.3 [M-H]−.
Compound 13: Pale yellow solid, Isolated yield: 44% (8.9 mg); RP-HPLC purity: 99%. 1H NMR
(500 MHz, DMSO-d6): 12.62 (1H, s), 10.99 (1H, br s), 6.42 (1H, s), 6.39 (1H, d, J = 1.9 Hz), 6.20 (1H, d,
J = 1.9 Hz), 3.82 (1H, septet, J = 6.1 Hz), 2.55 (2H, m), 2.42 (2H, m), 2.13–2.21 (4H, m), 1.02 (6H, d,
J = 6.1 Hz). 13C NMR (125 MHz, DMSO-d6): 209.2, 181.7, 169.0, 164.8, 161.4, 157.5, 108.0, 103.9, 99.1,
93.9, 75.0, 66.1, 2 × 36.1, 2 × 31.6, 2 × 24.0. ESI-MS (m/z): 331.4 [M-H]−.
Compound 15: Pale yellow solid, Isolated yield: 63.1% (12.6 mg); RP-HPLC purity: 98.9%.
1H NMR (500 MHz, DMSO-d6): 12.73 (1H, s), 6.41 (1H, s), 6.38 (1H, d, J = 1.9 Hz), 6.18 (1H, d, J = 1.9 Hz),
6.08 (1H, br s), 2 × 2.26 * (d, J = 4.7 Hz), 2 × 2.17* (d, J = 4.7 Hz). 13C NMR (125 MHz, DMSO-d6):
209.6, 182.0, 174.3, 164.5, 161.4, 157.6, 104.7, 103.6, 98.9, 94.0, 70.2, 2 × 35.7, 2 × 33.7. ESI-MS (m/z):
293.5 [M-H]−.
Compound 16: White solid, Isolated yield: 40.5% (8.2 mg); RP-HPLC purity: 95%. 1H NMR
(500 MHz, DMSO-d6): 12.65 (1H, s), 10.96 (1H, br s), 6.39 (1H, d, J = 1.9 Hz), 6.34 (1H, s), 6.20 (1H,
d, J = 1.9 Hz), 3.21 (3H, s), 2.52* (br d, J = 6.1 Hz) 2.33* (br d, J = 6.1 Hz), 2 × 2.18* (m). 13C NMR
(125 MHz, DMSO-d6): 209.1, 181.7, 168.9, 164.6, 161.4, 157.8, 107.6, 103.8, 99.0, 94.1, 75.7, 51.0, 2 × 35.4,
2 × 30.4. ESI-MS (m/z): 307.4 [M-H]−.
Compound 17: Pale pink solid, Isolated yield: 60.6% (12.1 mg); RP-HPLC purity: 96%. 1H NMR
(500 MHz, DMSO-d6): 12.66 (1H, s), 10.94 (1H, br s), 6.39 (1H, d, J = 1.9 Hz), 6.32 (1H, s), 6.21 (1H, d,
J = 1.9 Hz), 3.40 (2H, q, J = 6.9 Hz), 2.54* (br d, J = 6.0 Hz), 2.32* (br d, J = 6.0 Hz), 2 × 2.17* (m), 1.16
(3H, t, J = 6.9 Hz). 13C NMR (125 MHz, DMSO-d6): 209.1, 181.7, 169.5, 164.6, 161.4, 157.7, 107.1, 103.8,
99.0, 94.0, 75.4, 58.6, 2 × 35.5, 2 × 30.9, 15.5. ESI-MS (m/z): 321.3 [M-H]−.
Compound 18: White solid, Isolated yield: 51.4% (10.4 mg); RP-HPLC purity: 98%. 1H NMR
(500 MHz, DMSO-d6): 12.64 (1H, s), 10.97 (1H, br s), 6.38 (1H, d, J = 1.9 Hz), 6.32 (1H, s), 6.20 (1H, d,
J = 1.9 Hz), 3.30 (2H, t, J = 6.3 Hz), 2.53* (br d, J = 6.1 Hz), 2.34* (br d, J = 6.1 Hz), 2 × 2.17* (m), 1.55
(2H, m), 0.88 (3H, t, J = 7.3 Hz). 13C NMR (125 MHz, DMSO-d6): 209.6, 182.1, 169.7, 165.1, 161.9, 158.2,
107.8, 104.3, 99.5, 94.5, 75.5, 64.9, 2 × 35.9, 2 × 31.3, 23.2, 11.1. ESI-MS (m/z): 335.5 [M-H]−.
Compound 19: White solid, Isolated yield: 55.8% (11.3 mg); RP-HPLC purity: 99%. 1H NMR
(500 MHz, DMSO-d6): 12.62 (1H, s), 11.01 (1H, br s), 6.42 (1H, s), 6.39 (1H, d, J = 1.9 Hz), 6.21 (1H,
d, J = 1.9 Hz), 3.81 (1H, septet, J = 6.1 Hz), 2.53* (br d, J = 5.9 Hz), 2.39* (br d, J = 5.9 Hz), 2.17* (m),
2.13* (m), 1.01 (6H, d, J = 6.1 Hz). 13C NMR (125 MHz, DMSO-d6): 209.4, 181.7, 169.0, 164.8, 161.4,
157.5, 108.0, 103.8, 99.1, 93.9, 75.0, 66.0, 2 × 35.7, 2 × 31.2, 2 × 24.0. ESI-MS (m/z): 335.5 [M-H]−.
Compound 20: White solid, Isolated yield: 73.5% (14.7 mg); RP-HPLC purity: 99%. 1H NMR
(500 MHz, DMSO-d6): 12.64 (1H, s), 10.98 (1H, br s), 6.37 (1H, d, J = 1.7 Hz), 6.32 (1H, s), 6.19 (1H, d,
J = 1.7 Hz), 3.33 (2H, overlap with H2O signal, J = 5.7 Hz), 2.53* (br d, J = 6.1 Hz), 2.34* (br d, J = 6.1 Hz),
2 × 2.17 * (m), 1.52 (2H, m), 1.36 (2H, m), 0.85 (3H, t, J = 7.4 Hz). 13C NMR (125 MHz, DMSO-d6):
209.2, 181.6, 169.3, 164.7, 161.4, 157.7, 107.4, 103.8, 99.1, 94.0, 75.1, 62.5, 2 × 35.5, 31.6, 2 × 30.8, 18.9, 13.8.
ESI-MS (m/z): 349.8 [M-H]−.
Racemate 21: Pale brown solid; Isolated yield: 24.3% (41.67 mg); RP-HPLC purity at 241 nm:
99.5%. 1H NMR (500 MHz, DMSO-d6): 12.69 (1H, s), 11.45 (1H, s), 6.50 (1H, d, J = 10.1 Hz), 6.35 (1H, s),
6.34 (1H, d, J = 1.8 Hz), 6.32 (1H, d, J = 10.1 Hz), 6.20 (1H, d, J = 1.8 Hz), 3.91 (1H, septet, J = 6.1 Hz),
3.71 (1H, dd, J = 10.0 and 4.4 Hz), 3.18 (3H, s), 3.01 (1H, dd, J = 16.7 and 4.4 Hz), 2.43 (1H, dd, J = 16.7
and 10.0 Hz), 1.11 (3H, d, J = 6.1 Hz), 1.07 (3H, d, J = 6.1 Hz). 13C NMR (125 MHz, DMSO-d6): 181.5,
169.9, 164.6, 161.5, 157.6, 152.3, 130.1, 129.9, 108.4, 103.9, 99.1, 94.0, 79.0, 77.9, 67.6, 57.3, 24.03, 24.02,
23.6. ESI-MS (m/z): 374.7 [M-H]−.
Racemate 22: Pale brown solid; Isolated yield: 27.8% (47.43 mg); RP-HPLC purity at 247 nm:
99.9%. 1H NMR (500 MHz, DMSO-d6): 12.68 (1H, s), 11.43 (1H, br s), 6.48 (1H, d, J = 10.0 Hz), 6.33 (1H,
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d, J = 2.0 Hz), 6.29 (1H, d, J = 10.0 Hz), 6.25 (1H, s), 6.21 (1H, d, J = 2.0 Hz), 3.76 (1H, dd, J = 10.1 and
4.7 Hz), 3.43 (2H, m), 3.18 (3H, s), 3.03 (1H, dd, J = 16.8 and 4.7 Hz), 2.45 (1H, dd, J = 16.8 and 10.2 Hz),
1.50 (2H, m), 1.32 (2H, m), 0.85 (3H, t, J = 7.4 Hz). 13C NMR (125 MHz, DMSO-d6): 181.4, 168.5, 164.5,
161.5, 157.8, 152.2, 130.1, 129.7, 108.2, 103.9, 99.1, 94.0, 78.6, 77.7, 64.1, 57.5, 31.8, 23.7, 18.8, 13.7. ESI-MS
(m/z): 388.0 [M-H]−.
Racemate 23: Pale brown solid; Isolated yield: 25.1% (43.11 mg); RP-HPLC purity at 248 nm:
99.8%. 1H NMR (500 MHz, DMSO-d6): 12.67 (1H, s), 11.52 (1H, s), 6.52 (1H, d, J = 10.0 Hz), 6.33 (1H, d,
J = 1.9 Hz), 6.32 (1H, s), 6.29 (1H, d, J = 10.0 Hz), 6.21 (1H, d, J = 1.9 Hz), 4.27 (1H, dd, J = 15.7 and
2.3 Hz), 4.18 (1H, dd, J = 15.7 and 2.3 Hz), 3.80 (1H, dd, J = 10.2 and 4.7 Hz), 3.46 (1H, t, J = 2.3 Hz),
3.18 (3H, s), 3.07 (1H, dd, J = 16.7 and 4.7 Hz), 2.43 (1H, dd, J = 16.7 and 10.2 Hz). 13C NMR (125 MHz,
DMSO-d6): 181.5, 167.8, 164.5, 161.5, 157.7, 152.1, 130.8, 128.7, 108.4, 104.0, 99.1, 94.1, 80.5, 78.33, 78.31,
77.5, 57.4, 53.3, 23.7. ESI-MS (m/z): 370.3 [M-H]−.
Racemate 24: Pale brown solid; Isolated yield: 29.6% (50.76 mg); RP-HPLC purity at 246 nm:
97.3%. 1H NMR (500 MHz, DMSO-d6): 12.66 (1H, s), 11.38 (1H, s), 6.47 (3H, m, overlapping signals),
6.36 (1H, d, J = 1.9 Hz), 6.21 (1H, d, J = 1.9 Hz), 3.84–3.92 (2H, m, overlapping signals), 3.12 (1H, dd,
J = 12.3 and 4.2 Hz), 3.10 (3H, s), 2.52 (1H, dd, J = 3.4 Hz; partially overlapped with DMSO signal),
1.04 (3H, d, J = 6.1 Hz), 0.97 (3H, d, J = 6.1 Hz). 13C NMR (125 MHz, DMSO-d6): 181.5, 168.7, 164.7,
161.5, 157.4, 151.1, 130.1, 127.3, 108.9, 103.9, 99.1, 93.8, 78.2, 76.6, 66.6, 56.9, 24.4, 23.8, 22.7. ESI-MS (m/z):
374.7 [M-H]−.
Racemate 25: Pale brown solid; Isolated yield: 33.2% (56.64 mg); RP-HPLC purity at 247 nm:
99.7%. 1H NMR (500 MHz, DMSO-d6): 12.65 (1H, br s), 11.39 (1H, s), 10.92 (1H, br s), 6.48 (1H, d,
J = 10.3 Hz), 6.42 (1H, s), 6.36 (1H, d, J = 10.3 Hz), 6.32 (1H, d, J = 2.1 Hz), 6.21 (1H, d, J = 2.1 Hz), 3.90
(1H, br t, J = 4.3 Hz), 3.45 (1H, m), 3.28 (1H, m), 3.15 (3H, s), 3.02 (1H, dd, J = 17.4 and 5.1 Hz), 2.61
(1H, dd, J = 17.4 and 3.9 Hz), 1.45 (2H, m), 1.30 (2H, m), 0.82 (3H, t, J = 7.4 Hz). 13C NMR (125 MHz,
DMSO-d6): 181.5, 168.0, 164.5, 161.5, 157.5, 151.1, 130.1, 127.6, 108.7, 103.9, 99.1, 93.8, 78.0, 77.3, 62.8,
57.2, 31.6, 23.3, 18.7, 13.6. ESI-MS (m/z): 388.2 [M-H]−.
Racemate 26: Pale brown solid; Isolated yield: 31.8% (54.62 mg); RP-HPLC purity at 248 nm:
97.3%. 1H NMR (500 MHz, DMSO-d6): 12.65 (1H, s), 11.48 (1H, s), 6.53 (1H, d, J = 10.3 Hz), 6.44 (1H, s),
6.40 (1H, d, J = 10.3 Hz), 6.34 (1H, d, J = 1.9 Hz), 6.20 (1H, d, J = 1.9 Hz), 4.21 (1H, dd, J = 15.8 and
2.3 Hz), 4.15 (1H, dd, J = 15.8 and 2.3 Hz), 3.93 (1H, dd, J = 4.6 and 3.6 Hz), 3.39 (1H, t, J = 2.3 Hz),
3.14 (3H, s), 3.04 (1H, dd, J = 17.4 and 4.6 Hz), 2.57 (1H, dd, J = 17.4 and 3.6 Hz). 13C NMR (125 MHz,
DMSO-d6): 181.5, 167.1, 164.6, 161.5, 157.5, 151.0, 131.1, 126.0, 109.0, 104.0, 99.1, 93.9, 80.3, 77.9, 77.6,
77.4, 57.2, 52.1, 23.1. ESI-MS (m/z): 370.2 [M-H]−.
Racemate 27: Pale white solid; Isolated yield: 48.3% (30.5 mg); RP-HPLC purity at 247 nm: 96.1%.
1H NMR (500 MHz, DMSO-d6): 12.75 (1H, s), 10.34 (1H, s), 6.37 (1H, d, J = 1.9 Hz), 6.36 (1H, s), 6.18
(1H, d, J = 1.9 Hz), 5.84 (1H, br s), 3.08 (1H, br d, J = 14.2 Hz), 2.45 (1H, td, J = 13.4 and 4.9 Hz), 2.21 (1H,
m), 2.06 (1H, m), 1.98 (1H, td, J = 12.9 and 4.6 Hz), 1.80–1.89 (3H, m, overlapping signals). 13C NMR
(125 MHz, DMSO-d6): 182.1, 174.9, 164.4, 161.4, 157.6, 155.4, 104.5, 103.6, 98.9, 94.0, 71.2, 34.6, 33.3, 26.3,
18.8. ESI-MS (m/z): 304.4 [M-H]−.
Racemate 28: Pale white solid; Isolated yield: 42.1% (26.4 mg); RP-HPLC purity at 250 nm: 96.6%.
1H NMR (500 MHz, DMSO-d6): 12.66 (1H, s), 10.36 (1H, s), 6.38 (1H, d, J = 1.9 Hz), 6.27 (1H, s), 6.19
(1H, d, J = 1.9 Hz), 3.28 (2H, t, J = 6.1 Hz), 3.05 (1H, br d, J = 14.4 Hz), 2.33 (1H, td, J = 13.9 and 5.4 Hz),
2.16–2.23 (3H, m, overlapping signals), 1.98 (1H, td, J = 13.6 and 5.1 Hz), 1.87 (1H, td, J = 14.2 and
4.3 Hz), 1.78 (1H, td, J = 13.3 and 4.6 Hz), 1.49 (2H, m), 1.35 (2H, m), 0.84 (3H, t, J = 7.4 Hz). 13C NMR
(125 MHz, DMSO-d6): 181.7, 170.0, 164.5, 161.4, 157.7, 155.0, 107.1, 103.8, 99.0, 94.0, 76.0, 62.2, 31.8, 31.6,
30.6, 26.2, 18.9, 18.8, 13.8. ESI-MS (m/z): 360.5 [M-H]-.
3.3. Cell Lines and Viruses
The U373-CD4-CCR5 cell line was obtained from the AIDS Research and Reagent Program, NIAID.
Cells were cultured according to the protocol of the provider with 10% heat-inactivated fetal bovine
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serum (Lonza, Maastricht, The Netherlands) supplemented with 2 mM l-glutamine, 100 units/mL of
penicillin, and 100 µg/mL streptomycin (Invitrogen, Merelbeke, Belgium). Pseudotyped viral particules
bearing the ADA HIV Env were produced, as described previously [25].
EBV-positive BL cell line P3HR1 cells were cultured in RPMI 1640 medium [26,27]. Culture media
were supplemented with 10% fetal calf serum. P3HR1 cells were treated with 3 mM sodium butyrate
and 30 nM 12-O-tetradecanoylphobol-13-actetae (TPA) to induce the EBV lytic cycle [26,27].
3.4. Anti-HIV Testing
Antiviral activity was assessed while using a Pseudotype Virus Assay, allowing for one cycle of viral
replication [25]. The U373-CD4-CCR5 cells were infected by pseudotyped virus pNL4.3∆envLuc-ADA
8 using spinoculation at 1200 g during 2 h in the presence of compounds and cultured for two
consecutive days in the presence of the compounds. After 48 h, luciferase activity expressed as Relative
Light Units was measured (Luciferase System kit, Promega, The Netherlands). Drug cytotoxicity was
evaluated while using MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, Sigma,
Belgium) 48 h after incubation with the compounds by measuring A540 and A690 using a POLARstar
Omega Plate Reader (BMG Lab Technologies, Belgium) after 48 h of incubation with the compounds.
The value of OD540–OD690 was calculated.
3.5. Immunoblot Analysis of EBV Rta Protein
P3HR1 cells were lysed in mRIPA buffer (50 mM Tris-HCl, pH 7.8, 150 mM NaCl, 5 mM EDTA,
0.5% Triton X-100, 0.5% NP-40) [26,27]. Approximately 5% of the lysate was loaded to a gel and
then separated by electrophoresis in 10% SDS-PAGE. The proteins in the gel were electroblotted
onto a polyvinylidene difluoride (PVDF) blotting membrane while using a Hoefer transfer system.
Rta was detected while using mouse anti-Rta monoclonal antibody (Argene, Verniolle, France).
α-Tubulin was detected using mouse anti-α-tubulin monoclonal antibody (Abcam, Cambridge, UK).
Primary antibodies were detected using horseradish peroxidase-conjugated secondary antibodies
(Cell Signaling Technology, Danvers, MA, USA) and then visualized using SuperSignal West Pico
Chemiluminescent substrate (Thermo Fisher Scientific, Waltham, MA, USA).
3.6. Cytotoxicity Assay
P3HR1 cells (5 × 104) were seeded in wells of a 96-well plate and then cultured for 24 h in 100 µL
of RPMI 1640 medium containing protoapigenone or its analogs. Subsequently, 1% Triton X-100 was
added as a negative control. Cytotoxicity was determined by Cell Proliferation Kit I (Roche, Basel,
Switzerland). An aliquot of 10 µL of the MTT labeling reagent was added to each well and the plate
was incubated for 4 h at 37◦C. Afterwards, 100 µL solubilization solution was added to each well to
dissolve insoluble formazan and was incubated overnight. Optical density was measured at 595 nm
and 650 nm.
4. Conclusions
As a result of this work, the chemical space of non-cytotoxic protoflavonoids was significantly
extended through the preparation of derivatives without the symmetric dienone moiety, such as
saturated (hydrogenated or deuterated) B-ring and/or 4′-oxime containing protoflavones. Compound 9
was found to exert a weak antiretroviral activity that, due to the extremely low cytotoxicity
of this compound, might still be of interest. Further, three compounds, the isopropyl-, butyl-,
and propargyl-ether derivatives of protoapigenone were identified to act as potent anti-EBV agents
at similar, medium-low nanomolar concentration range as their parent compound 2. Importantly,
protoapigenone 1′-O-isopropyl ether demonstrated an order of magnitude lower cytotoxic effect when
compared to protoapigenone, which makes compound 6 ca. 2.6-times more selective anti-EBV agent.
Therefore, this compound can serve as a possible new lead for the development of safe and effective
protoflavone derivatives against the lytic cycle of EBV.
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Altogether, as a result of this work, it might also be concluded that targeted chemical modifications
of the protoflavone B-ring to decrease cytotoxicity represent a valid strategy towards the discovery of
new bioactive compounds against pathologies other than cancer.
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